Duncan Williams Starts Ironwood Pharmaceuticals (IRWD) at Hold, Sees More Attractive Entry Point in The Future
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Price: $4.31 +5.64%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Duncan Williams initiates coverage on shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) with a Hold rating and a fair value estimate of $15.
The firm believes that news of the Linaclotide approval is already priced into the stock and that any approval-related speculation could lead to negative volatility around the FDA panel and PDUFA in 2012 and actual approval may not drive share appreciation.
Duncan estimates that the company will only realize ~$1.7 billion in global Linaclotide royalties by 2027 based on sales of +$4.7 billion generated by its three existing partners, Forest Labs, Almirall, and Astellas.
The firm anticipates significant promotional expenses associated with global market creation for this category which also negatively impact the economics on the product, and therefor does not see the company attaining any profit from it before 2016, one year later than the consensus.
Duncan Williams forecasts $3.4 billion peak sales for Linaclotide in the US, with a profit split with Forest and $330 million peak Linaclotide royalty revenues from EU and Japan. The firm believes that additional financing may be required to get through the launch and expect more attractive entry points into the stock in the future.
For more ratings news on Ironwood Pharmaceuticals click here and for the rating history of Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $14.75 yesterday.
The firm believes that news of the Linaclotide approval is already priced into the stock and that any approval-related speculation could lead to negative volatility around the FDA panel and PDUFA in 2012 and actual approval may not drive share appreciation.
Duncan estimates that the company will only realize ~$1.7 billion in global Linaclotide royalties by 2027 based on sales of +$4.7 billion generated by its three existing partners, Forest Labs, Almirall, and Astellas.
The firm anticipates significant promotional expenses associated with global market creation for this category which also negatively impact the economics on the product, and therefor does not see the company attaining any profit from it before 2016, one year later than the consensus.
Duncan Williams forecasts $3.4 billion peak sales for Linaclotide in the US, with a profit split with Forest and $330 million peak Linaclotide royalty revenues from EU and Japan. The firm believes that additional financing may be required to get through the launch and expect more attractive entry points into the stock in the future.
For more ratings news on Ironwood Pharmaceuticals click here and for the rating history of Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $14.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- Oppenheimer Starts Carriage Services (CSV) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
